The Food and Drug Administration (FDA) has fully approved lecanemab (Leqembi) — a drug to slow the progression of early-stage Alzheimer’s disease —making it soon available to more than a million Medicare patients.

Experts from the USC Leonard D. Schaeffer Center for Health Policy & Economics, along with faculty from the USC Sol Price School of Public Policy, weigh in on the momentous development, as well as public policy regarding the availability of crucial new drugs.

To get their insights, click here.